News >

Bunn Expands on Significance of Atezolizumab/Bevacizumab Regimen in NSCLC

Danielle Bucco
Published: Tuesday, Jan 16, 2018

Paul A. Bunn Jr, MD

Paul A. Bunn Jr, MD
Findings from the phase III IMpower150 trial presented at the 2017 ESMO Immuno-Oncology Congress demonstrated that treatment with the combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with nonsquamous non–small cell lung cancer (NSCLC).

in Lung Cancer, shared his expert opinion on the IMpower150 study and other immunotherapy combinations in NSCLC.

OncLive: Can you discuss the results of the IMpower150 study?

Bunn: One issue about immunotherapy is that a minority of patients respond to it—that is, only about 20%. Therefore, we were wondering if you combined a single-agent checkpoint inhibitor with other immunotherapies, chemotherapies, or antiangiogenic agents, would you have a higher response rate and better overall outcome?
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication